A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone
in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy
in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit
than immediate release carbidopa/levodopa administered at the same levodopa dosage level of
100 mg three times a day (t.i.d.).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Carbidopa Carbidopa, levodopa drug combination Entacapone Levodopa